Study #2023-0308
NRG-BR008 ("HERO"): A Phase III randomized Trial Seeking to Optimize Use of Radiotherapy in Patients with Early-Stage, Low Risk, HER2-Positive Breast Cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
Description
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
HER2-positive Breast Cancer
Study phase:
Phase III
Physician name:
Melissa Mitchell
Department:
Radiation Oncology
For general questions about clinical trials:
1-844-996-5012
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.